1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Paion AG

Paion AG

0NF3.L
Paion AGGB flagLondon Stock Exchange

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription. 

Upgrade
Capital Structure

•

in mil. unless spec.
Working Capital

•

in mil. unless spec.
Growth Rates

•

in mil. unless spec.
Quarterly Revenue

•

in mil. unless spec.
Quarterly Earnings Per Share

•

in mil. unless spec.
Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO
Mr. Gregor Siebert
Full Time Employees
64
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
Heussstrasse 25 Aachen Germany 52078
IPO Date
Mar 10, 2023
Website
paion.com
Similar Companies
Business
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.